Ironwood Pharmaceuticals, Inc. — 2013 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2013; the filing also reports unaudited fourth-quarter results. Amounts are in U.S. dollars.
Business context
Ironwood is a pharmaceutical company focused on gastrointestinal medicines and guanylate cyclase pathways. Its lead and only marketed product is linaclotide: LINZESS in the U.S., marketed jointly with Forest for adult IBS-C and chronic idiopathic constipation (CIC), and CONSTELLA in Europe, marketed by Almirall for adult IBS-C. Canada approved CONSTELLA for adult IBS-C and CIC in December 2013. The company shares U.S. LINZESS profits or losses equally with Forest and is developing linaclotide with partners in China and Japan, alongside earlier-stage GI and soluble guanylate cyclase programs.
Financial performance and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Collaborative arrangements revenue | $22.9 million | $150.2 million |
| Total costs and expenses | $274.9 million | $223.0 million |
| Operating loss | $252.0 million | $72.8 million |
| Net loss | $272.8 million | $72.6 million |
| Net loss per share, basic and diluted | $2.35 | $0.68 |
| Net cash used in operating activities | $273.4 million | $69.6 million |
- FY 2013 R&D expense was $102.4 million, down 10%; selling, general and administrative expense was $123.2 million, up 33%; collaboration expense was $42.1 million, up from $16.0 million.
- Interest expense was $21.0 million, primarily reflecting the notes issued in January 2013. The company reported no income tax benefit in 2013.
- At year-end, cash and cash equivalents were $75.5 million and available-for-sale securities were $122.1 million, totaling $197.6 million. Working capital, excluding deferred revenue, was $193.2 million; total assets were $279.0 million and stockholders’ equity was $38.2 million.
- Net cash used in investing activities was $101.4 million, including $9.6 million of property and equipment purchases. Financing activities provided $313.6 million, principally from $175.0 million of notes and $137.8 million net proceeds from a stock offering.
- Year-end notes payable were $174.7 million, with an 11% annual interest rate; capital lease obligations were $4.3 million. Quarterly payments beginning March 2014 are based on the greater of accrued interest or 7.5% of prior-quarter U.S. LINZESS net sales, with excess applied to principal.
- There is no conventional operating margin to assess meaningfully given the company’s collaboration-based revenue and substantial development and commercialization costs.
Material changes versus prior periods
- Revenue fell 85% from 2012, largely because 2012 included $85.0 million of Forest milestones upon FDA approval, deferred-revenue amortization that ended in 2012, and $23.7 million of AstraZeneca license-related revenue. These items were not repeated at comparable levels in 2013.
- Despite the launch of LINZESS, the U.S. collaboration recorded a $73.0 million net loss for Ironwood’s share in 2013, compared with $21.1 million in 2012. Commercial and selling costs increased as the launch scaled.
- Net cash used in operations rose substantially, and cash, cash equivalents and available-for-sale securities together declined by approximately $29.4 million during 2013.
- Ironwood raised capital through both debt and equity offerings in 2013. Shares outstanding also increased; the company reported 103.1 million Class A and 18.4 million Class B shares outstanding as of January 28, 2014.
- Fourth-quarter 2013 collaborative revenue was $5.0 million and net loss was $52.0 million, versus revenue of $27.0 million and net loss of $43.9 million in fourth-quarter 2012.
Outlook, commentary and risks
- Management expected year-end cash and investments to fund projected operating needs for at least the next 12 months, but cautioned that actual cash use could exceed estimates. It anticipated substantial spending and losses for the foreseeable future and could not predict when, if ever, operations would become cash-flow positive or profitable. No specific earnings or revenue guidance was provided.
- Management’s priorities include growing LINZESS, supporting partner launches, extending linaclotide development, and advancing other GI and sGC programs. The company stated it would fund pipeline stages based on supportive data.
- In January 2014, Ironwood announced an approximately 10% workforce reduction, excluding field sales and medical science liaison teams. Expected severance and benefit charges were $4.0–$4.5 million, mostly cash, with completion anticipated in the first quarter of 2014.
- Key risks include reliance on U.S. LINZESS commercial performance and Forest collaboration economics; adverse events and post-approval requirements, including the pediatric boxed warning and studies; pricing, reimbursement and competition; partner execution; and reliance on contract manufacturers and limited raw-material sources.
- The notes’ debt service depends partly on Forest’s quarterly collaboration payments; Ironwood must cover any shortfall from general funds. Debt covenants restrict certain actions involving the Forest agreement and collateral, among other matters.
- Astellas’ Phase II Japanese study reported numerically higher responder rates than placebo but no statistically significant difference; analysis and next steps remained pending. A European opposition to one linaclotide patent was ongoing, although the company said other patents remained in force.
- The 2013 financial statements received an unqualified audit opinion. Management and the independent auditor concluded internal control over financial reporting was effective as of December 31, 2013. The filing listed no material legal proceedings.
Important facts for investors to verify
- LINZESS U.S. sales, collaboration costs, and the resulting quarterly profit-or-loss settlement with Forest.
- Cash burn and runway against management’s 12-month liquidity estimate, including the timing and amount of debt service.
- Progress on European reimbursement and launches, and the commercial contribution from CONSTELLA royalties and milestones.
- Manufacturing capacity, supply redundancy, and any supply or quality issues affecting linaclotide.
- Regulatory and clinical outcomes for pediatric post-marketing work, China Phase III development, and the Japanese program.
- Potential effects of the workforce reduction, patent opposition, contingent milestone commitments, and dilution from outstanding equity awards.